港股创新药回调，恒生创新药ETF（159316）获资金逆势布局

Group 1 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks primarily involved in innovative drug research and development [3] - As of the midday close, the index has increased by 0.5% with a rolling price-to-earnings ratio of 53.0 times, reflecting an 80.5% increase in valuation since its launch [4] Group 2 - The biotechnology ETF tracks the China Securities Biotechnology Theme Index, focusing on leading biotechnology companies in the A-share market, including those involved in gene diagnosis, biopharmaceuticals, and blood products [5] - As of the midday close, the biotechnology index has remained unchanged at 0.0% with a rolling price-to-earnings ratio of 55.6 times, indicating a 67.4% increase in valuation since its inception [5] Group 3 - The pharmaceutical ETF tracks the CSI 300 Healthcare Index, concentrating on leading companies in the A-share healthcare sector, covering segments such as chemical pharmaceuticals, medical services, and medical devices [6] - As of the midday close, the pharmaceutical index has increased by 0.2% with a rolling price-to-earnings ratio of 31.0 times, showing a 47.9% increase in valuation since its launch [7]